{"id":"avacincaptad-pegol","rwe":[],"_fda":{"id":"7fc0afa6-193a-413b-b5be-39c1069b1110","set_id":"1642fe6a-dc26-4d20-ae6e-654af744e3bd","openfda":{"unii":["K86ENL12I5"],"route":["INTRAVITREAL"],"rxcui":["2645112","2645118"],"spl_id":["7fc0afa6-193a-413b-b5be-39c1069b1110"],"brand_name":["IZERVAY"],"spl_set_id":["1642fe6a-dc26-4d20-ae6e-654af744e3bd"],"package_ndc":["82829-002-01","82829-002-99"],"product_ndc":["82829-002"],"generic_name":["AVACINCAPTAD PEGOL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AVACINCAPTAD PEGOL SODIUM"],"manufacturer_name":["Astellas Pharma US, Inc."],"application_number":["NDA217225"],"is_original_packager":[true]},"version":"9","pregnancy":["8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of IZERVAY administration in pregnant women. The use of IZERVAY may be considered following an assessment of the risks and benefits. Administration of avacincaptad pegol to pregnant rats and rabbits throughout the period of organogenesis resulted in no evidence of adverse effects to the fetus or pregnant female at intravenous (IV) doses 5.5 times and 3.4 times the human exposure, respectively, based on Area Under the Curve (AUC), following a single 2 mg intravitreal (IVT) dose (see Data ) . In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15%-20%, respectively. Data Animal Data An embryo fetal developmental toxicity study was conducted with pregnant rats. Pregnant rats received daily IV injections of avacincaptad pegol from day 6 to day 17 of gestation at 0.1, 0.4, 1.2 mg/kg/day. No maternal or embryofetal adverse effects were observed at any dose evaluated. An increase in the incidence of a non-adverse skeletal variation, described as short thoracolumbar (ossification site without distal cartilage) supernumerary ribs, was observed at all doses evaluated. The clinical relevance of this finding is unknown. Plasma exposures at the high dose were 5.5 times the human AUC of 999 ng•day/mL (23976 ng•hr/mL) following a single 2 mg IVT dose. An embryo fetal developmental toxicity study was conducted with pregnant rabbits. Pregnant rabbits received daily IV injections of avacincaptad pegol from day 7 to day 19 of gestation at 0.12, 0.4, 1.2 mg/kg/day. No maternal or embryofetal adverse effects were observed at any dose evaluated. Plasma exposure in pregnant rabbits at the highest dose of 1.2 mg/kg/day was 3.4 times the human AUC of 999 ng•day/mL (23976 ng•hr/mL) following a single 2 mg IVT dose."],"description":["11 DESCRIPTION IZERVAY contains avacincaptad pegol sodium, a complement C5 inhibitor. Avacincaptad pegol is a ribonucleic acid (RNA) aptamer, covalently bound to an approximately 43-kiloDalton (kDa) branched polyethylene glycol (PEG) molecule. The molecular formula of avacincaptad pegol (free acid form) is C 395 H 492 N 142 O 262 P 39 F 21 ((CH 2 ) 2 O) n where n~970 and the molecular weight is approximately 56 kDa. The structure of avacincaptad pegol sodium is presented below. IZERVAY (avacincaptad pegol intravitreal solution) is a sterile, clear to slightly opalescent, colorless to slightly yellowish solution in a single-dose glass vial for intravitreal administration. Each single-dose vial is designed to deliver 0.1 mL of solution containing 2 mg avacincaptad pegol (oligonucleotide basis), 0.198 mg dibasic sodium phosphate heptahydrate, 0.0256 mg monobasic sodium phosphate monohydrate, and 0.83 mg sodium chloride. IZERVAY is formulated in Water for Injection, with a target pH of 7.3. IZERVAY does not contain an anti-microbial preservative. Avacincaptad_Pegol"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied IZERVAY (avacincaptad pegol intravitreal solution) is supplied as a sterile, clear to slightly opalescent, colorless to slightly yellowish 20 mg/mL solution in a single-dose glass vial. Each glass vial contains an overfill amount to allow administration of a single 0.1 mL dose of solution containing 2 mg of avacincaptad pegol (oligonucleotide basis). Each IZERVAY carton (NDC 82829-002-01) contains one glass vial, one sterile 5-micron transfer filter needle (18-gauge x 1½ inch, 1.2 mm x 40 mm), and one sterile 1 mL Luer lock syringe. 16.2 Storage and Handling Store IZERVAY in the refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze. Do not shake. Keep the vial in the original carton to protect from light. Prior to use, the unopened glass vial of IZERVAY may be kept at room temperature, 20°C to 25°C (68°F to 77°F), for up to 24 hours. Ensure that the injection is given immediately after preparation of the dose.","16.1 How Supplied IZERVAY (avacincaptad pegol intravitreal solution) is supplied as a sterile, clear to slightly opalescent, colorless to slightly yellowish 20 mg/mL solution in a single-dose glass vial. Each glass vial contains an overfill amount to allow administration of a single 0.1 mL dose of solution containing 2 mg of avacincaptad pegol (oligonucleotide basis). Each IZERVAY carton (NDC 82829-002-01) contains one glass vial, one sterile 5-micron transfer filter needle (18-gauge x 1½ inch, 1.2 mm x 40 mm), and one sterile 1 mL Luer lock syringe."],"geriatric_use":["8.5 Geriatric Use Of the total number of patients who received IZERVAY in the two clinical trials, 90% (263/292) were ≥65 years and 61% (178/292) were ≥75 years of age. No significant differences in efficacy or safety of avacincaptad pegol were seen with increasing age in these studies. No dose adjustment is required in patients 65 years and above."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness of IZERVAY in pediatric patients have not been established."],"effective_time":"20260227","clinical_studies":["14 CLINICAL STUDIES The safety and efficacy of IZERVAY were demonstrated in two randomized, multi-center, double-masked, sham-controlled, 18- and 24-month studies (GATHER1-NCT02686658 and GATHER2-NCT04435366, respectively) in patients with GA due to AMD. Patient ages ranged from 51 to 97 years with a mean of 77 years. In total, 292 patients were treated with avacincaptad pegol 2 mg, and 332 patients received sham. In GATHER1, patients were treated with either IZERVAY or sham monthly for 18 months. In the primary analysis for GATHER1, the mean rate of GA growth (slope) from baseline to Month 12, measured by Fundus Autofluorescence (FAF), was evaluated at 3 time points: baseline, Month 6, and Month 12. Over a 12-month period, there was a statistically significant reduction of the rate of GA growth (0.10 mm/year; p<0.01 with square root transformed data) in patients treated with IZERVAY compared to sham. The observed results are shown in Table 3 and Figure 1 below. In the 24-month GATHER2 study, patients were treated with IZERVAY or sham monthly for the first 12 months. Patients receiving monthly IZERVAY were re-randomized at Month 12 to receive either IZERVAY monthly (EM) or every other month (EOM). Patients treated with sham in the first 12 months continued monthly sham treatment. At any time during the GATHER2 study, patients that developed choroidal neovascularization were concomitantly treated with anti-VEGF therapy. In GATHER2 analysis, the mean rate of GA growth (slope) measured by FAF was evaluated at 5 time points: baseline, Month 6, Month 12, Month 18, and Month 24. Over a 12-month period, there was a statistically significant reduction of the rate of GA growth (0.05 mm/year; p<0.01 with square root transformed data) in patients treated with IZERVAY EM compared to sham. The annualized rate of GA growth over 24 months in the monthly arm was 2.23 mm 2 /year, resulting in treatment difference versus sham of 0.36 mm 2 /year (p = 0.0165). In the treatment arm that included patients who received IZERVAY EM treatment for one year and EOM treatment for the second year, the annualized rate of GA growth was 2.10 mm 2 /year. The observed results for EM dosing are shown in Table 3 and Figure 2 below. In both studies, treatment effects in all pre-specified subgroups (e.g., age, gender, baseline GA disc area) were consistent with the results in the overall population. Table 3: Efficacy Outcomes of IZERVAY Monthly Dosing Compared to Sham in GATHER1 and GATHER2 a = non-transformed GA growth slope analysis b = % difference is calculated by 100*(difference)/(least squares mean from Sham) c = IZERVAY EM (IZERVAY monthly in both year 1 and year 2) MMRM= Mixed Models for Repeated Measures Efficacy Endpoint (MMRM Analysis) Month 12 Month 24 GATHER1 GATHER2 GATHER2 IZERVAY N=67 Sham N=110 IZERVAY N=225 Sham N=222 IZERVAY c N=96 Sham N=203 GA Rate of Growth (mm 2 /year) (observed) a 1.22 1.89 1.75 2.12 2.23 2.59 Difference (95% CI) (mm 2 /year) Difference % b p value 0.67 (0.21-1.13) 35% <0.01 0.38 (0.12-0.63) 18% <0.01 0.36 (0.07 – 0.66) 14% 0.0165 Figure 1: Mean Change in GA Area (mm 2 ) From Baseline in GATHER1 (Observed data) Figure 2: Mean Change in GA Area (mm 2 ) From Baseline in GATHER2 (Observed data) EM: monthly Figure 1 Figure 2"],"pharmacodynamics":["12.2 Pharmacodynamics Increased GA area growth is reflective of loss of photoreceptors and AMD disease progression. Reductions in the rate of GA growth were observed across avacincaptad pegol treatment groups in studies GATHER1 and GATHER2."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption/Distribution Following monthly dosing of avacincaptad pegol, at steady‑state maximum avacincaptad pegol plasma concentrations (C max ) are estimated to occur approximately 3 days post-dose and geometric mean (GeoCV%) free avacincaptad pegol plasma C max is estimated to be 347 ng/mL (59.0%) in GA secondary to AMD patients. The AUC 0-τ days following monthly dosing is 4726 day∙ng/mL, where tau is 28 days. In humans, avacincaptad pegol plasma concentrations are predicted to be approximately 1,400-fold lower than vitreal concentrations. Metabolism/Elimination Metabolism and elimination of avacincaptad pegol has not been fully characterized. Avacincaptad pegol is expected to be catabolized by endonucleases and exonucleases to oligonucleotides of shorter lengths. The estimated apparent systemic half-life of avacincaptad pegol is approximately 8 days. Specific Populations Following repeat monthly intravitreal dose administration of 2 mg avacincaptad pegol, no differences in the systemic pharmacokinetics of avacincaptad pegol were observed based on age, gender, and body weight. No special dosage modification is required for any of the populations that have been studied (e.g., age, gender, and body weight). The effect of severe renal impairment or any degree of hepatic impairment on the pharmacokinetics of avacincaptad pegol is unknown. As significant increases in plasma avacincaptad pegol exposures are not expected with intravitreal route of administration, no dosage adjustment is needed based on renal or hepatic impairment status."],"adverse_reactions":["6 ADVERSE REACTIONS The following potentially serious adverse reactions are described elsewhere in the labeling: • Ocular and periocular infections [see Contraindications (4.1) ] • Active intraocular inflammation [see Contraindications (4.2) ] • Endophthalmitis and retinal detachments [see Warnings and Precautions (5.1) ] • Neovascular AMD [see Warnings and Precautions (5.2) ] • Increase in intraocular pressure [see Warnings and Precautions (5.3) ] The most common adverse reactions (incidence ≥ 5%) were conjunctival hemorrhage, increased IOP, blurred vision, neovascular age-related macular degeneration, punctate keratitis, and eye pain ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of avacincaptad pegol was evaluated in 733 patients with AMD in two sham-controlled studies (GATHER1 and GATHER2). Of these patients, 292 were treated with intravitreal IZERVAY 2 mg (0.1 mL of 20 mg/mL solution) [see Clinical Studies (14) ] . Three hundred thirty-two (332) patients were assigned to sham. Adverse reactions reported in ≥2% of patients who received treatment with IZERVAY for up to 12 months pooled across the GATHER1 and GATHER2 studies are listed below in Table 1 . Table 1: Common Ocular Adverse Reactions (≥2%) and greater than Sham in Study Eye up to 12 months 1 Blurred vision includes visual impairment, vision blurred, visual acuity reduced, visual acuity reduced transiently. Adverse Drug Reactions IZERVAY N=292 Sham N=332 Conjunctival hemorrhage 13% 9% Increased IOP 9% 1% Blurred vision 1 8% 5% Choroidal neovascularization 7% 4% Eye pain 4% 3% Vitreous floaters 2% <1% Blepharitis 2% <1% Adverse reactions reported in ≥ 2% of patients who received treatment with IZERVAY for up to 24 months in the GATHER2 study are listed below in Table 2 . Table 2: Common Ocular Adverse Reactions (≥ 2%) and greater than Sham in Study Eye up to 24 months 1 Blurred vision includes visual impairment, vision blurred, visual acuity reduces, visual acuity reduced transiently and blindness transient. 2 Punctate keratitis includes punctate keratitis and keratitis. Adverse Drug Reactions IZERVAY (N=225) Sham (N=222) Conjunctival hemorrhage 17% 9% Blurred vision 1 14% 5% Increased IOP 13% 1% Choroidal neovascularization 12% 9% Punctate keratitis 2 10% 8% Eye pain 7% 4% Retinal hemorrhage 4% 3% Vitreous floaters 4% <1% Ocular hypertension 4% 0 Blepharitis 3% <1% Corneal abrasion 2% <1% Photopsia, optic ischemic neuropathy, vitreous hemorrhage, vitreal cells, vitritis, and endophthalmitis were each reported in ≤ 1% of patients treated with IZERVAY for up to 24 months across the GATHER1 and GATHER2 studies."],"contraindications":["4 CONTRAINDICATIONS • Ocular or periocular infections ( 4.1 ). • Active intraocular inflammation ( 4.2 ). 4.1 Ocular or Periocular Infections IZERVAY is contraindicated in patients with ocular or periocular infections. 4.2 Active Intraocular Inflammation IZERVAY is contraindicated in patients with active intraocular inflammation."],"mechanism_of_action":["12.1 Mechanism of Action Avacincaptad pegol is an RNA aptamer, a PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation."],"recent_major_changes":["Warnings and Precautions, Neovascular AMD ( 5.2 ) 2/2025"],"storage_and_handling":["16.2 Storage and Handling Store IZERVAY in the refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze. Do not shake. Keep the vial in the original carton to protect from light. Prior to use, the unopened glass vial of IZERVAY may be kept at room temperature, 20°C to 25°C (68°F to 77°F), for up to 24 hours. Ensure that the injection is given immediately after preparation of the dose."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Avacincaptad pegol is an RNA aptamer, a PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation. 12.2 Pharmacodynamics Increased GA area growth is reflective of loss of photoreceptors and AMD disease progression. Reductions in the rate of GA growth were observed across avacincaptad pegol treatment groups in studies GATHER1 and GATHER2. 12.3 Pharmacokinetics Absorption/Distribution Following monthly dosing of avacincaptad pegol, at steady‑state maximum avacincaptad pegol plasma concentrations (C max ) are estimated to occur approximately 3 days post-dose and geometric mean (GeoCV%) free avacincaptad pegol plasma C max is estimated to be 347 ng/mL (59.0%) in GA secondary to AMD patients. The AUC 0-τ days following monthly dosing is 4726 day∙ng/mL, where tau is 28 days. In humans, avacincaptad pegol plasma concentrations are predicted to be approximately 1,400-fold lower than vitreal concentrations. Metabolism/Elimination Metabolism and elimination of avacincaptad pegol has not been fully characterized. Avacincaptad pegol is expected to be catabolized by endonucleases and exonucleases to oligonucleotides of shorter lengths. The estimated apparent systemic half-life of avacincaptad pegol is approximately 8 days. Specific Populations Following repeat monthly intravitreal dose administration of 2 mg avacincaptad pegol, no differences in the systemic pharmacokinetics of avacincaptad pegol were observed based on age, gender, and body weight. No special dosage modification is required for any of the populations that have been studied (e.g., age, gender, and body weight). The effect of severe renal impairment or any degree of hepatic impairment on the pharmacokinetics of avacincaptad pegol is unknown. As significant increases in plasma avacincaptad pegol exposures are not expected with intravitreal route of administration, no dosage adjustment is needed based on renal or hepatic impairment status. 12.6 Immunogenicity The observed incidence of anti‑drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the study described below with the incidence of ADA in other studies. In the 18‑month treatment period in study ISEE2009, the incidence of anti‑avacincaptad pegol antibody formation was 1.1% (3 of 268 IZERVAY‑treated patients post treatment). Because of the low occurrence of ADA, the effect of these antibodies on the pharmacokinetics and/or safety of IZERVAY is unknown. The effect of anti‑avacincaptad pegol antibody on the pharmacodynamics and/or effectiveness of IZERVAY is also unknown."],"indications_and_usage":["1 INDICATIONS AND USAGE IZERVAY ® is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) ( 1 )."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Endophthalmitis and Retinal Detachments ( 5.1 ). • Neovascular AMD ( 5.2 ) • Increase in Intraocular Pressure (IOP) ( 5.3 ). 5.1 Endophthalmitis and Retinal Detachments Intravitreal injections may be associated with endophthalmitis and retinal detachments [see Adverse Reactions (6.1) ] . Proper aseptic injection techniques must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis [see Dosage and Administration (2.4) ] . Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management [see Patient Counseling Information (17) ] . 5.2 Neovascular AMD In the GATHER1 and GATHER2 clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD. 5.3 Increase in Intraocular Pressure Transient increases in intraocular pressure (IOP) have been observed after an intravitreal injection, including with IZERVAY [see Adverse Reactions (6.1) ] . Perfusion of the optic nerve head should be monitored following the injection and managed as needed [see Dosage and Administration (2.4) ] ."],"clinical_studies_table":["
Table 3: Efficacy Outcomes of IZERVAY Monthly Dosing Compared to Sham in GATHER1 and GATHER2
a = non-transformed GA growth slope analysis
b = % difference is calculated by 100*(difference)/(least squares mean from Sham)
c = IZERVAY EM (IZERVAY monthly in both year 1 and year 2) MMRM= Mixed Models for Repeated Measures
Efficacy Endpoint (MMRM Analysis)Month 12Month 24
GATHER1GATHER2GATHER2
IZERVAY N=67ShamN=110IZERVAY N=225ShamN=222IZERVAYc N=96ShamN=203
GA Rate of Growth (mm2/year) (observed)a1.221.891.752.122.232.59
Difference (95% CI) (mm2/year)Difference %bp value0.67 (0.21-1.13)35% <0.010.38 (0.12-0.63)18%<0.010.36 (0.07 – 0.66)14%0.0165
","
Figure 1: Mean Change in GA Area (mm2) From Baseline in GATHER1 (Observed data)
","
Figure 2: Mean Change in GA Area (mm2) From Baseline in GATHER2 (Observed data)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility Carcinogenesis No studies have been conducted on the carcinogenic potential of avacincaptad pegol. Mutagenesis Avacincaptad pegol was negative in in vitro (bacterial reverse mutation assay, chromosomal aberration in mammalian cells) and in vivo (mouse bone marrow micronucleus) assays. Impairment of Fertility Studies to evaluate the effect of avacincaptad pegol on male or female fertility in animals have not been performed."],"adverse_reactions_table":["
Table 1: Common Ocular Adverse Reactions (≥2%) and greater than Sham in Study Eye up to 12 months
1 Blurred vision includes visual impairment, vision blurred, visual acuity reduced, visual acuity reduced transiently.
Adverse Drug ReactionsIZERVAYN=292ShamN=332
Conjunctival hemorrhage13%9%
Increased IOP9%1%
Blurred vision18%5%
Choroidal neovascularization7%4%
Eye pain4%3%
Vitreous floaters2%<1%
Blepharitis2%<1%
","
Table 2: Common Ocular Adverse Reactions (≥ 2%) and greater than Sham in Study Eye up to 24 months
1 Blurred vision includes visual impairment, vision blurred, visual acuity reduces, visual acuity reduced transiently and blindness transient.
2 Punctate keratitis includes punctate keratitis and keratitis.
Adverse Drug ReactionsIZERVAY (N=225)Sham (N=222)
Conjunctival hemorrhage17%9%
Blurred vision114%5%
Increased IOP13%1%
Choroidal neovascularization12%9%
Punctate keratitis210%8%
Eye pain7%4%
Retinal hemorrhage4%3%
Vitreous floaters4%<1%
Ocular hypertension4%0
Blepharitis3%<1%
Corneal abrasion2%<1%
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise patients that following IZERVAY administration, patients are at risk of developing neovascular AMD, endophthalmitis, elevated intraocular pressure and retinal detachments. If the eye becomes red, sensitive to light, painful, or if a patient develops a change in vision, instruct the patient to seek immediate care from an ophthalmologist [see Warnings and Precautions (5.1 , 5.2) ] . Patients may experience temporary visual disturbances and blurring after an intravitreal injection with IZERVAY and the associated eye examinations [see Adverse Reactions (6.1) ] . Advise patients not to drive or use machinery until visual function has recovered sufficiently. IZERVAY ® (avacincaptad pegol intravitreal solution) Distributed by: Astellas Pharma US, Inc. Northbrook, IL 60062 ©2026 Astellas Pharma US, Inc. or its affiliates -00035-ACP-USA"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended dosage for IZERVAY is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately 28 ± 7 days) ( 2.2 ). 2.1 General Dosing Information IZERVAY must be administered by a qualified physician. 2.2 Recommended Dosage The recommended dosage for IZERVAY is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately every 28 ± 7 days). 2.3 Preparation for Administration Important information you should know before you begin: • Read all the instructions carefully before using IZERVAY. • The IZERVAY kit includes a glass vial, filter needle, and an empty syringe. The glass vial, filter needle, and empty syringe are for single use only. • Store IZERVAY in the refrigerator at temperatures between 2ºC to 8ºC (36ºF to 46ºF). Do not freeze. Do not shake. • Prior to use, allow IZERVAY to reach room temperature, 20⁰C to 25⁰C (68⁰F to 77⁰F). The IZERVAY vial may be kept at room temperature for up to 24 hours. Keep the vial in the original carton to protect from light. • Use aseptic technique to carry out the preparation of the intravitreal injection. • Each vial should only be used for the treatment of a single eye. Step 1: Gather Supplies Gather the following supplies ( see Figure A ): a. One IZERVAY vial (included) b. One sterile 5-micron filter needle 18-gauge x 1½ inch (included) c. One sterile 1 mL Luer lock syringe with a 0.1 mL dose mark (included) d. One sterile injection needle 30‑gauge x ½ inch (not included) NOTE: a 30-gauge injection needle is recommended to avoid increased injection forces that could be experienced with smaller diameter needles. e. Alcohol swab (not included) Figure A Step 2: Inspect Vial Inspect the liquid in the vial. It should be a clear to slightly opalescent, colorless to slightly yellow liquid solution ( see Figure B ). Do not use if particulates, cloudiness, or discoloration are visible. Do not use if the packaging, vial, filter needle, injection needle, and/or empty syringe are expired, damaged, or have been tampered with. Figure B Step 3: Orient Vial Place the vial upright on a flat surface for about 1 minute after removal from packaging to make sure all liquid settles at the bottom of the vial (see Figure C ) . Gently tap the vial with your finger to remove any liquid that may stick to the top of the vial (see Figure D ) . Figure C ______________________________________ Figure D Step 4: Clean Vial Remove the flip-off cap from the vial ( see Figure E ). Gently wipe the vial septum with an alcohol swab ( see Figure F ). Figure E Figure F Step 5: Attach Filter Needle Using aseptic technique, firmly attach the included 18-gauge x 1½ inch filter needle onto the 1 mL Luer lock syringe and twist clockwise to secure (see Figure G ) . Figure G Step 6: Insert Filter Needle into Vial Using aseptic technique, push the filter needle all the way into the center of the vial septum (see Figure H ) . Tilt the vial slightly so that the needle touches the bottom edge of the vial (see Figure I ) . Rotate the filter needle so that the bevel is submerged into the liquid to avoid introduction of air. Figure H Figure I Step 7: Withdraw Liquid Slowly withdraw all the liquid from the vial ( see Figure J ). Draw the plunger rod back far enough to completely empty the filter needle. Figure J Step 8: Disconnect Filter Needle Disconnect the filter needle from the syringe and dispose of it in accordance with local regulations ( see Figure K ). Do not use the filter needle for the intravitreal injection. Figure K Step 9: Attach Injection Needle Using aseptic technique, firmly attach the 30-gauge x ½ inch injection needle onto the Luer lock syringe. ( see Figure L ). Carefully remove the plastic needle shield from the needle by pulling it straight off ( see Figure M ). Figure L ________________________________________ Figure M Step 10: Check Syringe Check for air bubbles by holding the syringe with the needle pointing up. If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see Figure N ) . Figure N Step 11: Prepare Appropriate Dose Slowly depress the plunger to: • Expel the air from the syringe • Align the rubber stopper tip to the 0.1 mL dose mark. The syringe is now ready for the injection (see Figure O ) . Make sure to give the injection immediately after preparing the dose. Figure O Figure A Figure B Figure C Figure D Figure E and F Figure G Figure H and I Figure J Figure K Figure L Figure M Figure N Figure O 2.4 Injection Procedure Only 0.1 mL (2 mg) should be administered to deliver a single dose. Any excess volume should be disposed. Prior to the intravitreal injection, patients should be monitored for elevated intraocular pressure (IOP) using tonometry [see Warnings and Precautions (5.3) ] . If necessary, ocular hypotensive medication can be given to lower the IOP. The intravitreal injection procedure must be carried out under controlled aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum topical microbicide should be given prior to the injection. Inject slowly until the rubber stopper reaches the end of the syringe to deliver the volume of 0.1 mL. Confirm delivery of the full dose by checking that the rubber stopper has reached the end of the syringe barrel. Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure (IOP). Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. Following intravitreal injection, patients should be instructed to report any symptoms suggestive of endophthalmitis (e.g., eye pain, redness of the eye, photophobia, blurring of vision) without delay [see Patient Counseling Information (17) ] . Each vial and syringe should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial and syringe should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter needle, and injection needle should be changed before IZERVAY is administered to the other eye. Repeat the same procedure steps as above. Any unused medicinal product or waste material should be disposed of in accordance with local regulations."],"spl_product_data_elements":["IZERVAY avacincaptad pegol AVACINCAPTAD PEGOL SODIUM AVACINCAPTAD PEGOL SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE SODIUM CHLORIDE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Intravitreal solution: 20 mg/mL clear to slightly opalescent, colorless to slightly yellow solution in a single-dose vial. Intravitreal solution: 20 mg/mL in a single-dose vial ( 3 )."],"recent_major_changes_table":["
Warnings and Precautions, Neovascular AMD (5.2)2/2025
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of IZERVAY administration in pregnant women. The use of IZERVAY may be considered following an assessment of the risks and benefits. Administration of avacincaptad pegol to pregnant rats and rabbits throughout the period of organogenesis resulted in no evidence of adverse effects to the fetus or pregnant female at intravenous (IV) doses 5.5 times and 3.4 times the human exposure, respectively, based on Area Under the Curve (AUC), following a single 2 mg intravitreal (IVT) dose (see Data ) . In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15%-20%, respectively. Data Animal Data An embryo fetal developmental toxicity study was conducted with pregnant rats. Pregnant rats received daily IV injections of avacincaptad pegol from day 6 to day 17 of gestation at 0.1, 0.4, 1.2 mg/kg/day. No maternal or embryofetal adverse effects were observed at any dose evaluated. An increase in the incidence of a non-adverse skeletal variation, described as short thoracolumbar (ossification site without distal cartilage) supernumerary ribs, was observed at all doses evaluated. The clinical relevance of this finding is unknown. Plasma exposures at the high dose were 5.5 times the human AUC of 999 ng•day/mL (23976 ng•hr/mL) following a single 2 mg IVT dose. An embryo fetal developmental toxicity study was conducted with pregnant rabbits. Pregnant rabbits received daily IV injections of avacincaptad pegol from day 7 to day 19 of gestation at 0.12, 0.4, 1.2 mg/kg/day. No maternal or embryofetal adverse effects were observed at any dose evaluated. Plasma exposure in pregnant rabbits at the highest dose of 1.2 mg/kg/day was 3.4 times the human AUC of 999 ng•day/mL (23976 ng•hr/mL) following a single 2 mg IVT dose. 8.2 Lactation Risk Summary There is no information regarding the presence of avacincaptad pegol in human milk, the effects of the drug on the breastfed infant, or the effects of avacincaptad pegol on milk production. Many drugs are transferred in human milk with the potential for absorption and adverse reactions in the breastfed child. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for IZERVAY, and any potential adverse effects on the breastfed infant from IZERVAY. 8.4 Pediatric Use Safety and effectiveness of IZERVAY in pediatric patients have not been established. 8.5 Geriatric Use Of the total number of patients who received IZERVAY in the two clinical trials, 90% (263/292) were ≥65 years and 61% (178/292) were ≥75 years of age. No significant differences in efficacy or safety of avacincaptad pegol were seen with increasing age in these studies. No dose adjustment is required in patients 65 years and above."],"dosage_and_administration_table":["One IZERVAY vial (included)One sterile 5-micron filter needle 18-gauge x 1½ inch (included)One sterile 1 mL Luer lock syringe with a 0.1 mL dose mark (included)One sterile injection needle 30‑gauge x ½ inch (not included)NOTE: a 30-gauge injection needle is recommended to avoid increased injection forces that could be experienced with smaller diameter needles.Alcohol swab (not included)
Step 1: Gather Supplies Gather the following supplies (see Figure A):
a.b.c.d. e.
Figure A
","Do not use if particulates, cloudiness, or discoloration are visible. Do not use if the packaging, vial, filter needle, injection needle, and/or empty syringe are expired, damaged, or have been tampered with.
Step 2: Inspect Vial Inspect the liquid in the vial. It should be a clear to slightly opalescent, colorless to slightly yellow liquid solution (see Figure B).
Figure B
","
Step 3: Orient Vial Place the vial upright on a flat surface for about 1 minute after removal from packaging to make sure all liquid settles at the bottom of the vial (see Figure C). Gently tap the vial with your finger to remove any liquid that may stick to the top of the vial (see Figure D). Figure C______________________________________ Figure D
","
Step 4: Clean Vial Remove the flip-off cap from the vial (see Figure E). Gently wipe the vial septum with an alcohol swab (see Figure F). Figure E Figure F
","
Step 5: Attach Filter Needle Using aseptic technique, firmly attach the included 18-gauge x 1½ inch filter needle onto the 1 mL Luer lock syringe and twist clockwise to secure (see Figure G). Figure G
","
Step 6: Insert Filter Needle into Vial Using aseptic technique, push the filter needle all the way into the center of the vial septum (see Figure H). Tilt the vial slightly so that the needle touches the bottom edge of the vial (see Figure I). Rotate the filter needle so that the bevel is submerged into the liquid to avoid introduction of air. Figure H Figure I
","
Step 7: Withdraw Liquid Slowly withdraw all the liquid from the vial (see Figure J). Draw the plunger rod back far enough to completely empty the filter needle. Figure J
","
Step 8: Disconnect Filter Needle Disconnect the filter needle from the syringe and dispose of it in accordance with local regulations (see Figure K). Do not use the filter needle for the intravitreal injection. Figure K
","
Step 9: Attach Injection Needle Using aseptic technique, firmly attach the 30-gauge x ½ inch injection needle onto the Luer lock syringe. (see Figure L).Carefully remove the plastic needle shield from the needle by pulling it straight off (see Figure M). Figure L________________________________________ Figure M
","
Step 10: Check Syringe Check for air bubbles by holding the syringe with the needle pointing up. If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see Figure N). Figure N
","Expel the air from the syringe Align the rubber stopper tip to the 0.1 mL dose mark. The syringe is now ready for the injection (see Figure O). Make sure to give the injection immediately after preparing the dose.
Step 11: Prepare Appropriate Dose Slowly depress the plunger to:
••
Figure O
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC: 82829-002-01 izervay ™ (avacincaptad pegol intravitreal solution) 2 mg 0.1 mL of 20 mg/mL For intravitreal injection Single-Dose Vial Discard unused portion Refrigerate at 2°C to 8°C (36°F to 46°F) Astellas Pharma US, Inc. Rx only Figure","PRINCIPAL DISPLAY PANEL NDC: 82829-002-01 izervay ™ (avacincaptad pegol intravitreal solution) 2 mg (0.1 mL of 20 mg/mL solution) For Intravitreal Injection Single-Dose Vial Carton contents: -one IZERVAY ™ vial -one filter needle -one syringe Rx only Figure","PRINCIPAL DISPLAY PANEL NDC: 82829-002-99 izervay ™ (avacincaptad pegol intravitreal solution) 2 mg 0.1 mL of 20 mg/mL For intravitreal injection Single-Dose Vial Discard unused portion Refrigerate at 2°C to 8°C (36°F to 46°F) Astellas Pharma US, Inc. Sample-Not for Sale Figure","PRINCIPAL DISPLAY PANEL NDC: 82829-002-99 izervay ™ (avacincaptad pegol intravitreal solution) 2 mg (0.1 mL of 20 mg/mL solution) For Intravitreal Injection Single-Dose Vial Carton contents: -one IZERVAY ™ vial -one filter needle -one syringe Sample-Not for Sale Figure"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility Carcinogenesis No studies have been conducted on the carcinogenic potential of avacincaptad pegol. Mutagenesis Avacincaptad pegol was negative in in vitro (bacterial reverse mutation assay, chromosomal aberration in mammalian cells) and in vivo (mouse bone marrow micronucleus) assays. Impairment of Fertility Studies to evaluate the effect of avacincaptad pegol on male or female fertility in animals have not been performed."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Complement C5","category":"target"},{"label":"C5","category":"gene"},{"label":"Intravitreal","category":"route"},{"label":"Injection","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Geographic atrophy secondary to age-related macular degeneration","category":"indication"},{"label":"Astellas","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Conjunctival hemorrhage","drugRate":"13%","_validated":true,"placeboRate":"9%"},{"effect":"Increased IOP","drugRate":"9%","_validated":true,"placeboRate":"1%"},{"effect":"Blurred vision","drugRate":"8%","_validated":true,"placeboRate":"5%"},{"effect":"Choroidal neovascularization","drugRate":"7%","_validated":true,"placeboRate":"4%"},{"effect":"Eye pain","drugRate":"4%","_validated":true,"placeboRate":"3%"},{"effect":"Vitreous floaters","drugRate":"2%","_validated":true,"placeboRate":"<1%"},{"effect":"Blepharitis","drugRate":"2%","_validated":true,"placeboRate":"<1%"}],"contraindications":["IZERVAY is contraindicated in patients with ocular or periocular infections.","IZERVAY is contraindicated in patients with active intraocular inflammation."],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies of IZERVAY administration in pregnant women. The use of IZERVAY may be considered following an assessment of the risks and benefits.","Geriatric use":"No significant differences in efficacy or safety of avacincaptad pegol were seen with increasing age in these studies. No dose adjustment is required in patients 65 years and above.","Paediatric use":"Safety and effectiveness of IZERVAY in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Astellas Pharma","patents":[{"applNo":"N217225","source":"FDA Orange Book","status":"Active","expires":"Jul 11, 2034","useCode":"U-3673","territory":"US","drugProduct":false,"patentNumber":"11491176","drugSubstance":false},{"applNo":"N217225","source":"FDA Orange Book","status":"Active","expires":"Jul 11, 2034","useCode":"U-3673","territory":"US","drugProduct":false,"patentNumber":"11273171","drugSubstance":false},{"applNo":"N217225","source":"FDA Orange Book","status":"Active","expires":"Feb 14, 2027","useCode":"U-3673","territory":"US","drugProduct":false,"patentNumber":"9617546","drugSubstance":true},{"applNo":"N217225","source":"FDA Orange Book","status":"Active","expires":"Nov 11, 2026","useCode":"U-3673","territory":"US","drugProduct":false,"patentNumber":"8236773","drugSubstance":false},{"applNo":"N217225","source":"FDA Orange Book","status":"Active","expires":"Jul 11, 2034","useCode":"U-3673","territory":"US","drugProduct":false,"patentNumber":"12016875","drugSubstance":false},{"applNo":"N217225","source":"FDA Orange Book","status":"Active","expires":"Feb 14, 2027","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7579456","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AVACINCAPTAD PEGOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:27:02.923414+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:26:59.366487+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:27:41.766231+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:27:08.643754+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AVACINCAPTAD PEGOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:27:08.977629+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:26:57.853309+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:27:33.930302+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:26:57.853331+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Complement C5 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:27:10.140326+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297889/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:27:09.808742+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following potentially serious adverse reactions are described elsewhere in the labeling: • Ocular and periocular infections [see Contraindications (4.1) ] • Active intraocular inflammation [see Contraindications (4.2) ] • Endophthalmitis and retinal detachments [see Warnings and Precautions (5.1) ] • Neovascular AMD [see Warnings and Precautions (5.2) ] • Increase in intraocular pressure [see Warnings and Precautions (5.3) ] The most common adverse reactions (incidence ≥ ","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:27:23.843625+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:27:28.016556+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA217225","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:26:57.853334+00:00"}},"allNames":"izervay","offLabel":[],"synonyms":["avacincaptad pegol","avacincaptad pegol sodium","ARC1905","izervay"],"timeline":[{"date":"2023-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from IVERIC BIO to Astellas"},{"date":"2023-08-04","type":"positive","source":"DrugCentral","milestone":"FDA approval (Iveric Bio)"},{"date":"2027-02-14","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 9617546 expires"}],"aiSummary":"Izervay, a complement C5 inhibitor developed by Astellas Pharma, is currently marketed for the treatment of geographic atrophy secondary to AMD. Its key strength lies in its mechanism of action, which directly targets the complement C5 protein, a critical component of the immune response implicated in the progression of GA. The primary risk to Izervay's market position is the presence of several competitors targeting the same pathway, including eculizumab, pozelimab, and off-patent drugs like oxaprozin and raloxifene.","brandName":"Izervay","ecosystem":[{"indication":"Geographic atrophy secondary to age-related macular degeneration","otherDrugs":[{"name":"pegcetacoplan","slug":"pegcetacoplan","company":"Apellis Pharmaceuticals Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Complement C5","novelty":"Follow-on","targets":[{"gene":"C5","source":"DrugCentral","target":"Complement C5","protein":"Complement C5"}],"modality":"Small Molecule","explanation":"Avacincaptad pegol is an RNA aptamer, PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation.","oneSentence":"Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response.","technicalDetail":"Izervay binds to Complement C5 through a covalent interaction, inhibiting its ability to cleave C5a and C5b, which are key components of the complement cascade involved in the inflammatory response."},"commercial":{"launchDate":"2023","_launchSource":"DrugCentral (FDA 2023-08-04, IVERIC BIO)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5739","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AVACINCAPTAD%20PEGOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AVACINCAPTAD PEGOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:51:47.475118","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T03:27:41.766545+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"carprofen","drugSlug":"carprofen","fdaApproval":"1987-12-31","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"eculizumab","drugSlug":"eculizumab","fdaApproval":"2007-03-16","relationship":"same-target"},{"drugName":"oxaprozin","drugSlug":"oxaprozin","fdaApproval":"1992-10-29","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"pozelimab","drugSlug":"pozelimab","fdaApproval":"2023-08-18","relationship":"same-target"},{"drugName":"raloxifene","drugSlug":"raloxifene","fdaApproval":"1997-12-09","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"ravulizumab","drugSlug":"ravulizumab","fdaApproval":"2018-12-21","relationship":"same-target"},{"drugName":"sulindac","drugSlug":"sulindac","fdaApproval":"1978-09-27","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"avacincaptad pegol","indications":{"approved":[{"id":"avacincaptad-pegol-geographic-atrophy-(ga)-second","name":"Geographic atrophy (GA) secondary to AMD","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)","diagnosticRequired":null,"brandNameForIndication":"Izervay"}],"offLabel":[],"pipeline":[]},"currentOwner":"Astellas","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"carprofen","brandName":"carprofen","genericName":"carprofen","approvalYear":"1987","relationship":"same-target"},{"drugId":"eculizumab","brandName":"eculizumab","genericName":"eculizumab","approvalYear":"2007","relationship":"same-target"},{"drugId":"oxaprozin","brandName":"oxaprozin","genericName":"oxaprozin","approvalYear":"1992","relationship":"same-target"},{"drugId":"pozelimab","brandName":"pozelimab","genericName":"pozelimab","approvalYear":"2023","relationship":"same-target"},{"drugId":"raloxifene","brandName":"raloxifene","genericName":"raloxifene","approvalYear":"1997","relationship":"same-target"},{"drugId":"ravulizumab","brandName":"ravulizumab","genericName":"ravulizumab","approvalYear":"2018","relationship":"same-target"},{"drugId":"sulindac","brandName":"sulindac","genericName":"sulindac","approvalYear":"1978","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05536297","phase":"PHASE3","title":"Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-09-26","conditions":["Geographic Atrophy","Age-Related Macular Degeneration"],"enrollment":278,"completionDate":"2025-04-10"},{"nctId":"NCT03364153","phase":"PHASE2","title":"Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-01-12","conditions":["Stargardt's Macular Dystrophy"],"enrollment":121,"completionDate":"2025-03-31"},{"nctId":"NCT06961370","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-16","conditions":["Geographic Atrophy","Age-related Macular Degeneration"],"enrollment":132,"completionDate":"2027-01-03"},{"nctId":"NCT06779773","phase":"","title":"A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-01-22","conditions":["Geographic Atrophy","Macular Degeneration"],"enrollment":1000,"completionDate":"2030-01-31"},{"nctId":"NCT06970665","phase":"PHASE4","title":"A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2025-07-08","conditions":["Geographic Atrophy","Age-Related Macular Degeneration"],"enrollment":20,"completionDate":"2027-06-30"},{"nctId":"NCT06659445","phase":"PHASE2","title":"Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD","status":"RECRUITING","sponsor":"ONL Therapeutics","startDate":"2025-10-28","conditions":["Geographic Atrophy (GA)","Age - Related Macular Degeneration (AMD)"],"enrollment":324,"completionDate":"2028-11"},{"nctId":"NCT04435366","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)","status":"COMPLETED","sponsor":"IVERIC bio, Inc.","isPivotal":true,"startDate":"2020-06-22","conditions":["Geographic Atrophy","Macular Degeneration"],"enrollment":448,"completionDate":"2023-08-22"},{"nctId":"NCT03362190","phase":"PHASE2","title":"ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2017-10-11","conditions":["Neovascular Age-related Macular Degeneration"],"enrollment":64,"completionDate":"2018-10-18"},{"nctId":"NCT02686658","phase":"PHASE2,PHASE3","title":"Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"IVERIC bio, Inc.","isPivotal":true,"startDate":"2015-12-15","conditions":["Geographic Atrophy","Dry Age-Related Macular Degeneration"],"enrollment":286,"completionDate":"2020-04-23"},{"nctId":"NCT02397954","phase":"PHASE2","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2015-03-12","conditions":["Idiopathic Polypoidal Choroidal Vasculopathy"],"enrollment":4,"completionDate":"2015-10-23"},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":["Neovascular Age-Related Macular Degeneration"],"enrollment":1,"completionDate":"2018-04-24"},{"nctId":"NCT00709527","phase":"PHASE1","title":"ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2008-10-16","conditions":["Neovascular Age-Related Macular Degeneration"],"enrollment":60,"completionDate":"2009-12-30"},{"nctId":"NCT00950638","phase":"PHASE1","title":"A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2009-07-16","conditions":["Dry Age-Related Macular Degeneration"],"enrollment":47,"completionDate":"2011-03-24"},{"nctId":"NCT03374670","phase":"PHASE2","title":"ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"WITHDRAWN","sponsor":"Ophthotech Corporation","startDate":"2018-11","conditions":["Idiopathic Polypoidal Choroidal Vasculopathy"],"enrollment":0,"completionDate":"2019-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT02686658","NCT04435366"],"administration":{"route":"Intravitreal","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVITREAL","productName":"IZERVAY"}]},"_patentsChecked":true,"crossReferences":{"UNII":"TT0V5JLG5B","INN_ID":"10099","RXNORM":"2645107","UMLSCUI":"C5139850","chemblId":"CHEMBL4297889","ChEMBL_ID":"CHEMBL4297889","KEGG_DRUG":"D11748","DRUGBANK_ID":"DB15165","IUPHAR_LIGAND_ID":"12857","SECONDARY_CAS_RN":"1613641-69-2"},"formularyStatus":[],"originalProduct":{"form":"INJECTION","route":"INTRAVITREAL","company":"IVERIC bio, Inc.","brandName":"IZERVAY","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2023-","companyName":"Iveric Bio","relationship":"Original Developer"},{"period":"present","companyName":"Astellas","relationship":"Current Owner"}],"publicationCount":68,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"Iveric Bio","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Astellas","companyId":"astellas","modality":"Oligonucleotide","firstApprovalDate":"2023","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"application withdrawn","approval_date":null,"mah":null,"brand_name_local":"Izelvay","application_number":"EMEA/H/C/006153"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Izelvay","application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":2},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T03:27:41.766545+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}